This section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentHighlights
Sign In or Create an Account
or View more offersArticle content
:
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
- David Khougazian appointed Group Chief Executive Officer to lead Chiesi’s next phase of innovation-driven growth, effective 15 October 2026.
- Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins Chiesi from Flagship Pioneering.
Article content
PARMA, Italy — Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development.
Article contentArticle content
Following a thorough selection process led by the Board of Directors, David will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group CFO.
Article contentMaria Paola ChiesiArticle content
, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovation has always been at the heart of Chiesi’s mission and long-term vision. David’s appointment reflects our ambition to accelerate this journey and strengthen Chiesi’s ability to innovate in a healthcare environment that is changing faster than ever. He brings a unique combination of global healthcare leadership, operational experience and exposure to some of the most dynamic areas of biotech innovation, which makes him exceptionally well positioned to guide Chiesi through this next chapter.
Article content
Article content
On behalf of the Board, I would like to express my sincere gratitude to Jean-Marc Bellemin for his commitment and stewardship during this transition period. I would also like to thank the entire Group Executive Leadership Team for their dedication and collective leadership, which have been instrumental in maintaining the Group’s focus and preparing the organization for the next steps.”
Article contentDavid Khougazian Article content
commented: “I am honored and excited to join Chiesi, a company widely recognized for its strong values, scientific excellence, entrepreneurial mindset and commitment to patients. The healthcare landscape is evolving rapidly, creating extraordinary opportunities to advance innovation and transform patient outcomes. Chiesi has built an impressive foundation, combining scientific expertise and a clear commitment to sustainable growth across generations.
Article content
Article content
I look forward to working alongside Chiesi colleagues around the world to further strengthen the Group’s innovation capabilities, advance its pipeline and partnerships, and create lasting value for patients, healthcare systems and society.”
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Chiesi remains firmly committed to executing its patient-centric strategy, advancing innovation across its therapeutic areas, and delivering sustainable growth for the benefit of patients, healthcare systems, communities and the planet.
Article contentAbout Chiesi Group
Article content
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
Article content
Article content
By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi meets verified standards for social and environmental business practices. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
Article content
Article content
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
Article content
Article content
For further information please visit
Article contentwww.chiesi.comArticle content
or the website of your local Chiesi affiliate.
Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content
https://www.businesswire.com/news/home/20260915411388/en/
Article contentArticle content
Contacts
Article contentPress Info: Article content
Article content
Anna Bonisoli Alquati, Head of Global External Communications:
Article content[email protected] Article content
Article content
Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail:
Article content[email protected] Article content
Article content
Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail:
Article content[email protected]Article content